Gisela Paulsen - Dec 16, 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Former President and COO
Signature
/s/ Gisela Paulsen
Stock symbol
OCX
Transactions as of
Dec 16, 2022
Transactions value $
$0
Form type
4
Date filed
12/20/2022, 03:05 PM
Previous filing
Aug 17, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCX Common Stock, no par value Disposed to Issuer $0 -175K -32.32% $0.00 367K Dec 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Disposed to Issuer $0 -172K -45.83% $0.00 203K Dec 16, 2022 Common Stock 172K $3.42 Direct F2
transaction OCX Option to Purchase Common Stock Disposed to Issuer $0 -70.3K -56.25% $0.00 54.7K Dec 16, 2022 Common Stock 70.3K $1.15 Direct F2
transaction OCX Option to Purchase Common Stock Disposed to Issuer $0 -125K -100% $0.00* 0 Dec 16, 2022 Common Stock 125K $1.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 16, 2022. Any remaining restricted stock units immediately vested on December 16, 2022.
F2 The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 16, 2022. Any remaining options immediately vested and became exercisable as of December 16, 2022.